These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 10627771

  • 1. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
    Lubin V, Charbonnel B, Bouchard P.
    Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
    [Abstract] [Full Text] [Related]

  • 2. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 3. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation.
    Dubourdieu S, Le Nestour E, Spitz IM, Charbonnel B, Bouchard P.
    Hum Reprod; 1993 Dec; 8(12):2056-60. PubMed ID: 8150903
    [Abstract] [Full Text] [Related]

  • 4. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP, Laven JS, Mulders AG, Oberyé JJ, Mannaerts BM, de Jong FH, Fauser BC.
    J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
    [Abstract] [Full Text] [Related]

  • 5. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
    Filicori M, Flamigni C, Campaniello E, Valdiserri A, Ferrari P, Meriggiola MC, Michelacci L, Pareschi A.
    J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
    [Abstract] [Full Text] [Related]

  • 6. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 7. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN, Phung HT, Ho MT.
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [Abstract] [Full Text] [Related]

  • 8. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
    Bahçeci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA.
    J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
    [Abstract] [Full Text] [Related]

  • 9. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
    Genazzani AD, Battaglia C, Gamba O, Petraglia F, Malavasi B, Genazzani AR.
    J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414
    [Abstract] [Full Text] [Related]

  • 10. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation.
    Ganor-Paz Y, Friedler-Mashiach Y, Ghetler Y, Hershko-Klement A, Berkovitz A, Gonen O, Shulman A, Wiser A.
    J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707
    [Abstract] [Full Text] [Related]

  • 11. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
    Christin-Maitre S, Olivennes F, Dubourdieu S, Chabbert-Buffet N, Charbonnel B, Frydman R, Bouchard P.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M, Liz-Lestón J, Lado-Abeal J.
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [Abstract] [Full Text] [Related]

  • 14. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
    Hayes FJ, Taylor AE, Martin KA, Hall JE.
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
    [Abstract] [Full Text] [Related]

  • 15. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
    Rossmanith WG, Wirth U, Benz R, Wolf AS.
    Gynecol Endocrinol; 1989 Jul; 3(1):21-34. PubMed ID: 2658471
    [Abstract] [Full Text] [Related]

  • 16. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
    Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH, Tzeng CR.
    Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
    [Abstract] [Full Text] [Related]

  • 17. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C.
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [Abstract] [Full Text] [Related]

  • 18. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
    Fulghesu AM, Ciampelli M, Belosi C, Apa R, Guido M, Caruso A, Mancuso S, Lanzone A.
    J Endocrinol Invest; 2001 Jan; 24(7):483-90. PubMed ID: 11508781
    [Abstract] [Full Text] [Related]

  • 19. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 20. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC, Cikot RJ, Dargel-Donkers EJ, Zwertbroek W, van Dop PA, Schoot DC.
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.